Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsDalbavancin in the treatment of complicated skin and soft-tissue infections: a reviewDalbavancin: a novel antimicrobialClinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)Dalbavancin for the treatment of acute bacterial skin and skin structure infectionsActivity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax modelTelavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensSelection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.Current and novel antibiotics against resistant Gram-positive bacteriaActivity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United StatesIn vivo pharmacodynamic activity of the glycopeptide dalbavancinFactors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)Investigational new drugs for the treatment of resistant pneumococcal infections.Dalbavancin: a new option for the treatment of gram-positive infections.Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteersRole of linezolid in the treatment of complicated skin and soft tissue infections.Dalbavancin: a novel lipoglycopeptide antibacterial.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Anthrax: an update.Review of dalbavancin, a novel semisynthetic lipoglycopeptide.Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.Antimicrobial therapy of Staphylococcus aureus bloodstream infection.Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.Vancomycin resistance: are there better glycopeptides coming?A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials.Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.Subinhibitory Dalbavancin Attenuates Exotoxin Production from Methicillin-sensitive and Methicillin-resistant Staphylococcus aureus in vitro.Antipneumococcal activity of dalbavancin compared to other agents.Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin.Bactericidal activity and resistance development profiling of dalbavancin.Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.
P2860
Q24646677-E754B0ED-7927-4EB8-BAFC-A18233F98CAEQ24647429-0A823CBB-233B-4A02-A61A-8B1A5EE52A4EQ24674841-6FC9D918-2B8E-41A9-9516-A4457EADB8FCQ26746208-D14549F7-0174-4F11-8BFD-923F140D9E3DQ26799598-CF52E0D8-5858-42CE-8217-3CF56B62C939Q33676316-EC9D0A93-2DD0-4066-B5DB-CA44357B1ED5Q33788308-A8D3C384-89A3-4A1E-B693-335663A8D5A2Q34719942-3BEB225B-57D8-44B7-97E9-B8FE9BC86608Q35026521-CC479694-2D31-4D3A-9C94-0D694AA61DDDQ35690571-F2B07FE1-83E1-4FAF-BB58-688CC9F57A05Q35759076-FF3C7985-814C-48F1-9D09-AAA94D636ED2Q36098775-ADBBF19A-A671-4560-80C7-CC655132E876Q36206406-DE0A4788-980D-4009-847B-FCACFE0E6192Q36210902-CF718581-B34A-4639-9C2A-F75B936686F2Q36409507-0CF51573-83D2-4C4F-9714-2883ED773818Q36490252-F1332524-3520-4645-8167-8B9C2B3D35A6Q36505478-FDEFC782-461A-430B-A527-02153C48841AQ36520635-703E15D2-91E8-4E3A-8DB6-C2944A083516Q36718474-1C5C414C-55B5-4203-8DEF-F4FAFC6CF8DDQ36734177-9F6E94BA-FF74-47D4-91F6-94CA62DBC138Q36802632-19C5D975-10C7-4AE4-8082-841F70D449CEQ36901937-69D6CE52-85FC-44FC-BF47-13C9E3786970Q36968150-91628202-CE38-409F-A8F1-A1EE6901B45FQ37077627-F7090013-4D3F-43FC-932F-40EBBC9C7F9CQ37340562-29F274DE-26F5-42E2-8B73-59E5ABFDB153Q37661510-574B29BD-B50A-4470-8A04-E7F116658FB8Q38137920-3908BD2D-5D2A-4FA6-BA58-1025E714840BQ38314386-AF1DA6F1-F57C-486C-9366-92EF0F4C19C9Q38536284-12D5071B-0614-451F-903E-1DA06E755CDEQ39042375-FE386684-D3A2-431B-9B47-C9B66CC3CB25Q40065964-505958A6-C469-4B29-8A7D-8E184C73C8FBQ40668272-2E974574-5796-459D-A2AE-32FF76941BF6Q40746046-0C28B7AB-09B1-4D85-84AD-14E69FC0B808Q41005410-110B9517-6260-48BE-88A1-851A7054E146Q41104208-841565A2-C6EE-4390-98A0-3C21C20A905BQ41839607-91A0A0C6-EE2D-4333-8C84-1DA97365D156Q41958813-543E26C3-0765-4579-8DC5-816018B0B71FQ42433025-2E22936F-5465-4BD2-AABF-CD68A625119EQ42550139-549F33F1-B4FD-450C-9E87-6140BA4ECB3DQ43066197-97572BCD-D008-47EA-9FDC-5BC1EBB125BC
P2860
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Worldwide assessment of dalbav ...... over 6,000 clinical isolates.
@en
Worldwide assessment of dalbav ...... over 6,000 clinical isolates.
@nl
type
label
Worldwide assessment of dalbav ...... over 6,000 clinical isolates.
@en
Worldwide assessment of dalbav ...... over 6,000 clinical isolates.
@nl
prefLabel
Worldwide assessment of dalbav ...... over 6,000 clinical isolates.
@en
Worldwide assessment of dalbav ...... over 6,000 clinical isolates.
@nl
P2093
P1476
Worldwide assessment of dalbav ...... over 6,000 clinical isolates.
@en
P2093
Jennifer M Streit
Ronald N Jones
Thomas R Fritsche
P304
P356
10.1016/J.DIAGMICROBIO.2003.09.004
P577
2004-02-01T00:00:00Z